VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MRNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MRNAModerna, Inc.
$206.80$82.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMRNAFinancials

Moderna, Inc. (MRNA) Income Statement

10Y historyFree accessUpdated daily

Revenue rebounded to $1.3B in Q3 2026 with a 75.8% gross margin, but the 9.9% operating margin follows multiple quarters of losses, including an operating margin of -126.4% in 2025Q4, suggesting the profit may be an isolated event.

Income StatementBalance SheetCash FlowRatios

MRNA Income Statement

Annual statement

MRNA Income Statement

Moderna, Inc. (MRNA) annual income statement — 10-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue2.52B1.94B3.2B6.85B18.88B17.74B803.39M60.21M135.07M205.82M108.4M
Revenue Growth %13.69%-39.23%-53.29%-63.72%6.42%2107.63%1234.34%-55.42%-34.38%89.88%-
Cost of Goods Sold1.82B868M1.46B4.69B5.42B2.62B39.18M31.02M24.86M20.54M15.11M
COGS % of Revenue-44.65%45.76%68.53%28.69%14.76%4.88%51.52%18.41%9.98%13.94%
Gross Profit707M1.08B1.74B2.15B13.46B15.12B764.21M29.19M110.21M185.29M93.28M
Gross Margin %28%55.35%54.24%31.47%71.31%85.24%95.12%48.48%81.59%90.02%86.06%
Gross Profit Growth %--37.98%-19.49%-83.99%-10.98%1878.38%2518.24%-73.52%-40.52%98.63%-
Operating Expenses3.64B4.15B5.68B6.39B4.04B1.82B1.53B574.91M94.25M454.64M317.05M
OpEx % of Revenue-213.48%177.56%93.37%21.4%10.28%190.11%954.85%69.78%220.89%292.5%
Selling, General & Admin979M1.02B1.17B1.55B1.13B567M188.27M109.62M94.25M64.72M57.45M
SG&A % of Revenue-52.37%36.7%22.62%6%3.2%23.43%182.07%69.78%31.45%53%
Research & Development2.66B3.13B4.54B4.84B3.29B1.99B1.37B496.31M454.08M410.46M274.72M
R&D % of Revenue-161.11%142.01%70.75%17.46%11.23%170.57%824.31%336.19%199.42%253.44%
Other Operating Expenses00-37M0-388M-735M-31.25M-31.02M-454.08M-20.54M-15.11M
Operating Income-2.93B-3.07B-3.94B-4.24B9.42B13.3B-763.14M-545.72M-468.87M-269.36M-223.77M
Operating Margin %-116.04%-158.13%-123.32%-61.9%49.91%74.97%-94.99%-906.38%-347.13%-130.87%-206.44%
Operating Income Growth %-22.08%6.94%-145%-29.15%1842.27%-39.84%-16.39%-74.07%-20.37%-
EBITDA-2.67B-2.86B-3.76B-3.62B9.77B13.53B-732.14M-514.7M-444M-248.82M-208.66M
EBITDA Margin %-105.86%-147.07%-117.41%-52.83%51.75%76.27%-91.13%-854.85%-328.73%-120.89%-192.5%
EBITDA Growth %17.88%23.88%-3.81%-137.04%-27.79%1947.72%-42.25%-15.92%-78.44%-19.25%-
D&A (Non-Cash Add-back)257M215M189M621M348M232M31M31.02M24.86M20.54M15.11M
EBIT-2.71B-2.77B-3.58B-3.9B9.6B13.3B-734.63M-508.1M-436.91M-255.86M-223.77M
Net Interest Income246M304M401M383M171M014.83M31.92M23.93M15.1M11.31M
Interest Income271M314M425M421M200M18M24.71M38.53M27.02M15.23M11.31M
Interest Expense25M10M24M38M29M18M9.89M6.61M3.1M132K0
Other Income/Expense201M306M338M297M155M-11M18.63M31M28.86M13.36M8.6M
Pretax Income-2.73B-2.77B-3.61B-3.94B9.57B13.29B-744.51M-514.72M-440.01M-256M-215.17M
Pretax Margin %-108.08%-142.39%-112.75%-57.56%50.73%74.9%-92.67%-854.88%-325.77%-124.38%-198.5%
Income Tax60M54M-46M772M1.21B1.08B2.55M-695K326K-80K1.04M
Effective Tax Rate %-2.2%-1.95%1.28%-19.58%12.67%8.15%-0.34%0.14%-0.07%0.03%-0.48%
Net Income-2.79B-2.82B-3.56B-4.71B8.36B12.2B-747.06M-514.02M-384.73M-255.92M-216.21M
Net Margin %-110.46%-145.16%-111.32%-68.84%44.3%68.8%-92.99%-853.73%-284.84%-124.34%-199.46%
Net Income Growth %10.49%20.75%24.46%-156.37%-31.47%1733.33%-45.34%-33.6%-50.34%-18.36%-
Net Income (Continuing)-2.79B-2.82B-3.56B-4.71B8.36B12.2B-747.06M-514.02M-384.73M-255.92M-216.21M
Discontinued Operations00000000000
Minority Interest00000000000
EPS (Diluted)-6.49-7.26-9.27-12.3420.1028.29-1.96-1.55-1.17-0.72-3.79
EPS Growth %12.14%21.68%24.88%-161.39%-28.95%1543.37%-26.45%-32.48%-62.5%81%-
EPS (Basic)--7.26-9.27-12.3421.2630.31-1.96-1.55-1.17-0.72-3.79
Diluted Shares Outstanding430M389M384M382M416M431M381.33M330.8M328.8M376M64.09M
Basic Shares Outstanding401M389M384M382M394M403M381.33M330.8M328.8M376M64.09M
Dividend Payout Ratio-----------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Revenue concentration and commercial execution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Quarterly Rebound Masks Trailing Revenue Decline

Based on the reported quarterly income statements, Moderna's Q3 2026 revenue of $1.3B represented 29.2% year-over-year growth, but trailing-twelve-month revenue remains down 39.2%, indicating the rebound has not yet offset the post-pandemic contraction.

The jump from $145.0M in Q2 2026 to $1.3B in Q3 2026 reflects the seasonal concentration of respiratory vaccine sales in the second half of the calendar year, which makes a single quarter a weak basis for judging durability. The reported figures suggest the company's top line is still resetting toward a smaller commercial demand base, so investors should monitor whether Q4 2026 sustains a comparable level of revenue rather than extrapolating one seasonal peak.

Gross Margin Swings Reflect Volume Dependence

As reported in the quarterly income statements, Moderna's gross margin ranged from 15.9% to 75.8% across recent quarters, with the Q3 2026 peak of 75.8% contrasting sharply with the 33.3% and 35.9% seen in adjacent periods.

Such wide swings suggest gross profit is driven more by the timing of high-volume shipments and milestone or collaboration revenue than by a stable unit-economics baseline. Underutilized manufacturing capacity appears to be weighing on cost absorption in weaker quarters, which may indicate that structural margins depend on sustained demand recovery. Investors should treat the Q3 2026 margin as a potentially non-recurring high point until it is confirmed across multiple periods.

Operating Losses Persist Despite Cost Discipline

Based on reported figures, Moderna's R&D spending remained above $580M in every recent quarter, while the operating margin still reached -158.1% on a trailing basis, implying fixed research and infrastructure costs continue to outpace gross profit.

R&D and SG&A together absorbed far more than gross profit in most periods, meaning operating income has been dominated by the size of the fixed cost base rather than by revenue scaling. The reported figures do not yet show operating income scaling faster than gross profit in a sustained way, which warrants further investigation into how quickly the cost base can adjust to lower pandemic-era volumes.

Q3 EPS Beat Requires Scrutiny

According to the reported Q3 2026 figures, Moderna's diluted EPS of $0.38 contrasted with a prior-quarter loss of $1.96 per share, but net income of $162.0M on $1.3B revenue implies a net margin of 12.3%, a level the company has not sustained in the period shown.

A swing from deep losses to a profit in a single quarter suggests the result may include one-time or timing-related items rather than purely recurring operating earnings. Stock-based compensation of $127.0M in the quarter remains a meaningful cost that the headline EPS may not fully reflect in its underlying trend. Investors should verify the composition of Q3 net income before treating the beat as evidence of a durable earnings inflection.

Sustained Losses Challenge the Inflection Thesis

Based on reported figures, Moderna's net margin of -145.2% on a trailing basis and cumulative quarterly losses exceeding $800M in several periods suggest the Q3 2026 profit may prove an isolated seasonal event rather than the start of sustained profitability.

The bear case centers on the fact that the company has posted losses in the large majority of quarters shown, and that a single profitable quarter does not offset the trailing deficit. If commercial market share erodes against entrenched incumbents, the high fixed-cost base could keep operating margins deeply negative. Investors should monitor whether subsequent quarters confirm the Q3 result or revert to the pattern of large operating losses.

MRNA — Frequently Asked Questions

Quick answers to the most common questions about buying MRNA stock.

What was Moderna, Inc.'s (MRNA) revenue in 2025?

For fiscal year 2025, Moderna, Inc. (MRNA) reported total revenue of $1.94B. This represents a 1693.4% increase compared to $108.4M in 2016.

Is Moderna, Inc. (MRNA) profitable?

Moderna, Inc. (MRNA) reported a net loss of $2.82B for the fiscal year ending 2025.

What is Moderna, Inc.'s operating profit margin?

Moderna, Inc. (MRNA) reported an operating income of $-3074.0M, resulting in an operating profit margin of -158.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Moderna, Inc.'s gross profit and gross margin?

Moderna, Inc. (MRNA) generated $1.08B in gross profit for the year, representing a gross profit margin of 55.3%. This demonstrates the company's core pricing power and production efficiency.